Last reviewed · How we verify
NCT05643027: ACTION
A Novel Intervention for Patients With Cancer
NA trial testing Acceptance and Commitment Therapy in Substance Use in 40 participants. Currently enrolling.
10 June 2026
Quick facts
| Lead sponsor | Dana-Farber Cancer Institute |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 40 |
| Start date | 1 March 2023 |
| Primary completion | 10 June 2026 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Acceptance and Commitment Therapy
Conditions studied
- Substance Use — all drugs for Substance Use →
- Cancer — all drugs for Cancer →
- Psychological — all drugs for Psychological →
Sponsor
Dana-Farber Cancer Institute
Who can join
Adults 18 to 99, any sex, with Substance Use or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study is being done to develop an intervention for psychological symptoms that patients diagnosed with cancer may experience. Psychological symptoms may include thoughts, feelings, emotions, and memories The names of the study intervention and research activities involved in this study are/is: * Acceptance \& Commitment Therapy (ACT) for Cancer (involving 6 sessions with a licensed clinical psychologist) * Questionnaires * Post-study interview Consistent with the NIH Stage Model for Behavioral Intervention Development, the investigators have adapted an existing, empirically-validated intervention, Acceptance and Commitment Therapy (ACT), to address substance use disorder risk during cancer care. The core components of ACT are particularly well-suited to address the psychological processes underlying opioid misuse in individuals treated for cancer pain. The overarching aim is to assess the feasibility and acceptability of the intervention by conducting a randomized pilot trial of the revised intervention ("ACTION") for cancer patients on opioid therapy, and at risk for SUD.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Study protocol for a pilot randomised controlled trial of a virtually delivered behavioural intervention (ACTION) for adults with cancer at risk for opioid use disorder.
Yusufov M, Pirl WF, Greer JA, Mazzola E, et al · · 2024 · PMID 39638585 · DOI 10.1136/bmjopen-2024-096546
Verify or expand the search:
- PubMed search for NCT05643027
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Acceptance and Commitment Therapy
Trials testing the same drug.
- NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges · NA · not yet recruiting
- NCT07345806 — A Pilot Study on an ACT-Based Program for Individuals With Special Needs and Their Caregivers · NA · recruiting
- NCT07512388 — Acceptance and Commitment Therapy for Post-Stroke Adjustment Via Telerehabilitation · NA · active not recruiting
- NCT06647589 — Acceptance and Commitment Therapy for Religious OCD · NA · recruiting
- NCT06971861 — Just ACT for Student Well-being · NA · recruiting
Other recruiting trials for Substance Use
Currently open trials in the same condition.
- NCT07075081 — Gii'Igoshimong: Sitting With Your First Family · Phase 2 · recruiting
- NCT05743699 — Adaptation and Evaluation of Bright Horizons · NA · recruiting
- NCT07509853 — Integrating Sexual Pleasure Into Harm Reduction Services for Men Who Have Sex With Men and Transgender Persons Who Engag · NA · recruiting
- NCT06899308 — Health Surveillance at Constructor University Bremen (CUB) and Among HAW-Hamburg Employees · recruiting
- NCT07512869 — Host Led Harm Reduction Approach Among Men Who Have Sex With Men Who Engaged in Chemsex in Bangkok, Thailand: A Pre-Impl · recruiting
Other Dana-Farber Cancer Institute trials
Trials by the same sponsor.
- NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
- NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
- NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
- NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
- NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05643027 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
- Last refreshed: 5 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05643027.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing